Advertisement
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
No AccessJournal of UrologyReview Article1 Dec 2015

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies

    View All Author Information

    Purpose:

    The availability of newly approved treatment options for metastatic castration resistant prostate cancer is not matched with conclusive data on optimal sequencing strategies and resistance patterns. A comprehensive review of efficacy and safety data for new agents and current knowledge regarding treatment sequencing would enable treating physicians to make rational drug selections in patients with metastatic castration resistant prostate cancer.

    Materials and Methods:

    We searched MEDLINE® and relevant congresses for data on cabazitaxel, docetaxel, 223radium dichloride, abiraterone, enzalutamide and sipuleucel-T, focusing on sequencing strategies, resistance mechanisms and biomarkers of response.

    Results:

    Abiraterone and enzalutamide target the androgen axis with different mechanisms of action. Abiraterone blocks cytochrome P450 17, inhibiting androgen synthesis, whereas enzalutamide inhibits androgen receptor, reducing nuclear translocation of the androgen receptor complex and subsequent DNA binding. Both agents provide improved overall survival in patients with metastatic castration resistant prostate cancer who received prior docetaxel treatment and in those who are chemotherapy naïve. Cabazitaxel provides improved overall survival in patients with metastatic castration resistant prostate cancer with prior docetaxel therapy. Sipuleucel-T provides improved overall survival in asymptomatic patients and 223radium provides improved overall survival in chemotherapy naïve and chemotherapy treated patients with symptomatic bone metastases. Selecting the correct treatment with metastatic castration resistant prostate cancer is complex as no head-to-head trials have been done and comparison between existing trials is difficult due to differences in study populations and a lack of validated biomarkers. Factors to consider include prior therapy, symptom burden, metastasis type, performance status, comorbidities, adverse event profiles and patient preference. Another consideration is treatment sequence since some agents affect responses to subsequent choices. For example, resistance to abiraterone or enzalutamide may result in limited responses to subsequent androgen targeted agents. Identifying factors predictive of resistance is an area of ongoing research with androgen receptor variants representing a good candidate. Prognostic factors for survival are also likely to be useful and are currently being studied.

    Conclusions:

    New therapies for metastatic castration resistant prostate cancer have brought new challenges with regard to treatment selection and sequencing. While hormonal agents provide good therapeutic responses, resistance may be intrinsic without prior drug exposure. Identifying predictors of response and relevant biomarkers will allow therapies to be more precisely tailored to individual patient profiles.

    References

    • 1 National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 2.2014). Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed June 2014. Google Scholar
    • 2 : Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med2011; 364: 1995. Google Scholar
    • 3 : Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med2012; 367: 1187. Crossref, MedlineGoogle Scholar
    • 4 : Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol2012; 13: 983. Crossref, MedlineGoogle Scholar
    • 5 : Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol2012; 13: 1210. Google Scholar
    • 6 : Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer2013; 49: 3648. Google Scholar
    • 7 : Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med2013; 368: 138. Google Scholar
    • 8 : Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol2014; 66: 815. Google Scholar
    • 9 : Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med2014; 371: 424. Google Scholar
    • 10 : Final overall survival (OS) analysis of COU-AA-302, a randomized Phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy. Ann Oncol2014; 25: iv255. Google Scholar
    • 11 : Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med2010; 363: 411. Google Scholar
    • 12 : Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet2010; 376: 1147. Crossref, MedlineGoogle Scholar
    • 13 : Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med2013; 369: 213. Google Scholar
    • 14 : Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases. J Clin Oncol2013; 31. abstract 5038. Google Scholar
    • 15 : Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol2014; 32. abstract LBA2. Google Scholar
    • 16 : Castration-resistant prostate cancer: AUA guideline. J Urol2013; 190: 429. LinkGoogle Scholar
    • 17 : CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. Can Urol Assoc J2013; 7: 231. Google Scholar
    • 18 : Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer2014; 50: 1617. Google Scholar
    • 19 : Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer2014; 120: 968. Google Scholar
    • 20 : Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol2014; 48: 268. Google Scholar
    • 21 : Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol2013; 24: 1807. Google Scholar
    • 22 : Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol2013; 24: 1802. Google Scholar
    • 23 : Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate2014; 74: 1278. Google Scholar
    • 24 : A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in docetaxel treated metastatic castrate-resistant prostate cancer patients. Eur J Cancer2013; 49. abstract 2904. Google Scholar
    • 25 : Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol2014; 66: 459. Google Scholar
    • 26 : Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis2014; 17: 34. Google Scholar
    • 27 : Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol2013; 31: 2791. Google Scholar
    • 28 : Efficacy outcomes by baseline prostate-specific antigen (PSA): results from the phase 3 AFFIRM trial. J Urol2013; 189. abstract 785. Google Scholar
    • 29 : Assessing the impact of prior treatments on the efficacy of enzalutamide (ENZ): a subanalysis of the phase 3 AFFIRM trial. Eur J Cancer2013; 49. abstract 2862. Google Scholar
    • 30 : Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol2006; 24: 3984. Google Scholar
    • 31 : Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. Future Oncol2014; 10: 985. Google Scholar
    • 32 : Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst2013; 105: 1729. Google Scholar
    • 33 : Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res2011; 17: 5913. Google Scholar
    • 34 : A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov2013; 3: 1020. Google Scholar
    • 35 : Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res2013; 73: 483. Google Scholar
    • 36 : Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol2012; 30: 637. Google Scholar
    • 37 : Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol2014; 67: 53. Google Scholar
    • 38 : Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302. J Clin Oncol2014; 32. abstract 5058. Google Scholar
    • 39 : Androgen receptor (AR) amplification in patients with metastatic castration-resistance prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). J Clin Oncol2014; 32. abstract 5020. Google Scholar
    • 40 : Genomic analysis of circulating tumor DNA (ctDNA) in plasma of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (abi) and enzalutamide (enza). J Clin Oncol2014; 32. abstract 5021. Google Scholar
    • 41 : ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol2013; 31. abstract 5004. Google Scholar
    • 42 : AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med2014; 371: 1028. Google Scholar
    • 43 Food and Drug Administration: Highlights of Prescribing Information. XTANDI® (enzalutamide) capsules for oral use. Initial U.S. Approval: 2012. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf. Accessed June 2014. Google Scholar
    • 44 : Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol2014; 32: 671. Google Scholar
    • 45 : External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone. Eur Urol2014; 66: 8. Google Scholar
    • 46 : A predictive algorithm for response to abiraterone in metastatic castration relapsed prostate cancer (CRPC). J Clin Oncol2014; 32. abstract 238. Google Scholar
    • 47 : Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol2014; 25: 657. Google Scholar
    • 48 : A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel. J Clin Oncol2013; 31. abstract 5013. Google Scholar
    • 49 : Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol2013; 24: 2402. Google Scholar
    • 50 : Prognostic factors for patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy. J Clin Oncol2014; 32. abstract e16054. Google Scholar
    Advertisement